Hu and Yo antibodies have heterogeneous avidity

Journal of Neuroimmunology

Volumn 185, Issue 1-2, 2007, Pages 162-167

  Totland, Cecilie ^a,b   Aarseth, Jan ^a,b   Vedeler, Christian ^a,b  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

Author keywords

Antibodies; Avidity; Hu; Paraneoplastic; Urea; Yo

Indexed keywords

ANTIBODY; BRAIN ANTIBODY; HU ANTIBODY; UNCLASSIFIED DRUG; UREA; YO ANTIBODY;

ANTIBODY AFFINITY; ARTICLE; CLINICAL ARTICLE; HUMAN; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; PARANEOPLASTIC NEUROPATHY; PATHOGENESIS; PRIORITY JOURNAL; SERUM; TIME;

ANIMALS; ANTIBODIES, NEOPLASM; ANTIBODY AFFINITY; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HU PARANEOPLASTIC ENCEPHALOMYELITIS ANTIGENS; HUMANS; IMMUNOPRECIPITATION; NERVE TISSUE PROTEINS; PARANEOPLASTIC SYNDROMES; RATS;

EID: 33947655413     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2007.01.016     Document Type: Article

References (31)

1. Achenbach P., Koczwara K., Knopff A., Naserke H., Ziegler A.-G., and Bonifacio E. Mature high-affinity immune responses to (pro)insulin anticipate the autoimmune cascade that leads to type 1 diabetes. J. Clin. Invest. 114 (2004) 589-597
2. Albert M.L., Darnell J.C., Bender A., Francisco L.M., Bhardwaj N., and Darnell R.B. Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Nat. Med. 4 (1998) 1321-1324
3. Albert M.L., Austin L.M., and Darnell R.B. Detection and treatment of activated T cells in the cerebrospinal fluid of patients with paraneoplastic cerebellar degeneration. Ann. Neurol. 47 (2000) 9-17
4. Amyes E., Curnow J., Stark Z., Corlett L., Sutton I., and Vincent A. Restricted IgG1 subclass of anti-Yo antibodies in paraneoplastic cerebellar degeneration. J. Neuroimmunol. 114 (2001) 259-264
5. Arias-Bouda L.M., Kuijper S., Van der Werf A., Nguyen L.N., Jansen H.M., and Kolk A.H. Changes in avidity and level of immunoglobulin G antibodies to Mycobacterium tuberculosis in sera of patients undergoing treatment for pulmonary tuberculosis. Clin. Diagn. Lab. Immunol. 10 (2003) 702-709
6. Devey M.E., Bleasdale-Barr K.M., Bird P., and Amlot P.L. Antibodies of different human IgG subclasses show distinct patterns of affinity maturation after immunization with keyhole limpet haemocyanin. Immunology 70 (1990) 168-174
7. Fish S., Zenowich E., Fleming M., and Manser T. Molecular analysis of original antigenic sin. I. Clonal selection, somatic mutation, and isotype switching during a memory B cell response. J. Exp. Med. 170 (1989) 1191-1209
8. Goidl E.A., Paul W.E., Siskind G.W., and Benacerraf B. The effect of antigen dose and time after immunization on the amount and affinity of anti-hapten antibody. J. Immunol. 100 (1968) 371-375
9. Graus F., Delattre J.Y., Antoine J.C., Dalmau J., Giometto B., Grisold W., Honnorat J., Smitt P.S., Vedeler C., Verschuuren J.J., Vincent A., and Voltz R. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J. Neurol. Neurosurg. Psychiatry 75 (2004) 1135-1140
10. Greenlee J.E., Boyden J.W., Pingree M., Brashear H.R., Clawson S.A., and Keeney P.M. Antibody types and IgG subclasses in paraneoplastic neurological syndromes. J. Neurol. Sci. 184 (2001) 131-137
11. Griffiths G.M., Berek C., Kaartinen M., and Milstein C. Somatic mutation and the maturation of immune response to 2-phenyl oxazolone. Nature 312 (1984) 271-275
12. Hedman K., and Rousseau S.A. Measurement of avidity of specific IgG for verification of recent primary rubella. J. Med. Virol. 27 (1989) 288-292
13. Hedman K., Lappalainen M., Seppaia I., and Makela O. Recent primary toxoplasma infection indicated by a low avidity of specific IgG. J. Infect. Dis. 159 (1989) 736-740
14. Holland G.P., Holland N., and Steward M.W. Interferon-gamma potentiates antibody affinity in mice with a genetically controlled defect in affinity maturation. Clin. Exp. Immunol. 82 (1990) 221-226
15. Joynson D.H., Payne R.A., and Rawal B.K. Potential role of IgG avidity for diagnosing toxoplasmosis. J. Clin. Pathol. 43 (1990) 1032-1033
16. Meurman O., Waris M., and Hedman K. Immunoglobulin G antibody avidity in patients with respiratory syncytial virus infection. J. Clin. Microbiol. 30 (1992) 1479-1484
17. Monstad S.E., Drivsholm L., Storstein A., Aarseth J.H., Haugen M., Lang B., Vincent A., and Vedeler C.A. Hu and voltage-gated calcium channel (VGCC) antibodies related to the prognosis of small-cell lung cancer. J. Clin. Oncol. 22 (2004) 795-800
18. Monstad S.E., Storstein A., Dorum A., Knudsen A., Lonning P.E., Salvesen H.B., Aarseth J.H., and Vedeler C.A. Yo antibodies in ovarian and breast cancer patients detected by a sensitive immunoprecipitation technique. Clin. Exp. Immunol. 144 (2006) 53-58
19. Persson M.A., Brown S.E., Steward M.W., Hammarstrom L., Smith C.I., Howard C.R., Wahl M., Rynnel-Dagoo B., Lefranc G., and Carbonara A.O. IgG subclass-associated affinity differences of specific antibodies in humans. J. Immunol. 140 (1988) 3875-3879
20. Roberts W.K., and Darnell R.B. Neuroimmunology of the paraneoplastic neurological degenerations. Curr. Opin. Immunol. 16 (2004) 616-622
21. Rossi C.L. A simple, rapid enzyme-linked immunosorbent assay for evaluating immunoglobin G antibody avidity in toxoplasmosis. Diagn. Microbiol. Infect. Dis. 30 (1998) 25-30
22. Rulli M., and Simell O. Avidity of islet cell autoantibodies in non-diabetic children and children with insulin-dependent diabetes. Autoimmunity 31 (1999) 187-193
23. Saalman R., Dahlgren U.I., Fallstrom S.P., Hanson L.A., Ahlstedt S., and Wold A.E. Avidity progression of dietary antibodies in healthy and coeliac children. Clin. Exp. Immunol. 134 (2003) 328-334
24. Steward M.W., and Lew A.M. The importance of antibody affinity in the performance of immunoassays for antibody. J. Immunol. Methods 78 (1985) 173-190
25. Steward M.W., Reinhardt M.C., and Staines N.A. The genetic control of antibody affinity. Evidence from breeding studies with mice selectively bred for either high or low affinity antibody production. Immunology 37 (1979) 697-703
26. Storstein A., Monstad S.E., Nakkestad H.L., Husebye E.S., and Vedeler C.A. Paraneoplastic antibodies against HuD detected by a sensitive radiobinding assay. J. Neurol. 251 (2004) 197-203
27. Tanaka M., Tanaka K., Tsuji S., Kawata A., Kojima S., Kurokawa T., Kira J., and Takiguchi M. Cytotoxic T cell activity against the peptide, AYRARALEL, from Yo protein of patients with the HLA A24 or B27 supertype and paraneoplastic cerebellar degeneration. J. Neurol. Sci. 188 (2001) 61-65
28. Tanaka M., Maruyama Y., Sugie M., Motizuki H., Kamakura K., and Tanaka K. Cytotoxic T cell activity against peptides of Hu protein in anti-Hu syndrome. J. Neurol. Sci. 201 (2002) 9-12
29. Villalta D., Romelli P.B., Savina C., Bizzaro N., Tozzoli R., Tonutti E., Ghirardello A., and Doria A. Anti-dsDNA antibody avidity determination by a simple reliable ELISA method for SLE diagnosis and monitoring. Lupus 12 (2003) 31-36
30. Vincent A., and Newsom-Davis J. Acetylcholine receptor antibody characteristics in myasthenia gravis. II. Patients with penicillamine-induced myasthenia or idiopathic myastenia of recent onset. Clin. Exp. Immunol. 49 (1982) 266-272
31. Westerlund A., Ankelo M., Ilonen J., Knip M., Simell O., and Hinkkanen A.E. Absence of avidity maturation of autoantibodies to the protein tyrosine phosphatase-like IA-2 molecule and glutamic acid decarboxylase (GAD65) during progression to type 1 diabetes. J. Autoimmun. 24 (2005) 153-167